PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32366411-0	2020	Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.	LY3009120	39-48	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	95-99	
32366411-2	2020	LY3009120, a newly discovered pan-RAF inhibitor, has shown strong antitumor effects in cancers with various BRAF genotypes.	LY3009120	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	108-112	
32366411-9	2020	CONCLUSION: LY3009120 is a potent therapeutic agent for patients with BRAF non-V600E mutant NSCLC.	LY3009120	12-21	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	70-74